Over 500 million men worldwide suffer from erectile dysfunction and premature ejaculation. Dicot Pharma is developing an entirely new potency drug aimed at creating a treatment with longer duration, fewer side effects, and effectiveness for a significantly broader group compared to existing market alternatives.
Dicot Pharma’s World in Numbers
Approx.
billion SEK/year
The global sales of erectile dysfunction treatments.
Approx.
percent
The proportion of men with erectile dysfunction who discontinue treatment with current medications.
At least
days
LIB-01's duration from exploratory measurements in the Phase 1 study.
percent
Subscription rate in the August 2024 rights issue.
Read Dicot Pharma's Annual Report 2024!
In the newly released Annual Report you'll find an exclusive interview with renowned sexual medicine expert Professor François Giuliano, insights into the clinical studies, a look at how the market could expand dramatically with the right triggers – and much more.
Important Patent Family Approved in the U.S.
The approval of all three patents in this family strengthens both product and method protection until 2042 in the key U.S. market.
